Please login to the form below

Not currently logged in
Email:
Password:

Pfizer revenue increase for 2010

Pfizer has announced an increase in revenue of 36 per cent for 2010, reflecting sales of drugs acquired after the company's takeover of Wyeth

Pfizer announced today its financial results for the fourth quarter of 2010, as well as full financial results for the year.

Full year revenue was up by 36 per cent, with the company bringing in $67.8bn over 2010. Recent sales increased too, with revenue for the fourth quarter of 2010 at $17.56bn.

Net income for the fourth quarter period was also up, rising by 277 per cent to $2.8bn.

The dramatic increase is due to extra revenue from products acquired from Wyeth, as well as 2009 results being affected by costs related to Pfizer's takeover of the company.

Pfizer was cautious in its outlook for the future however, with revenue targets for 2010 falling from between $65.2bn and $67.7bn to between $63bn and $65.5bn.

"After evaluating our operating plans and capital allocation opportunities," said Ian Read, president and CEO, Pfizer, "we have adjusted our 2012 revenue target to exclude the projected contribution from future business development transactions and have reallocated funding to support an attractive, near-term opportunity to significantly increase our share repurchase activity."

Read continued: "In addition, during 2011 we expect to complete our ongoing review of the composition of our business portfolio to determine the optimal mix of businesses that we can appropriately fund and manage in order to achieve consistent growth and maximum return on investment. We believe these decisions, taken together, will continue to improve our business profile and provide both near-term and longer-term financial benefit."

Pfizer also announced today the closure of its plant in Kent, England, with 2,400 jobs to be cut.

1st February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics